REMARKS

Docket No.: 04654/1200494-US1

Reconsideration of this application is respectfully requested. Claim 1 has been amended to correct typographical errors and to incorporate the limitations of claim 3. Claim 3 has been canceled without prejudice. Claims 17 and 18 have been amended to delete the definitions of the variables m and n, which are repetitive of the definitions provided in claim 1. Claim 92 has been added. Support for claim 92 can be found, for example, in Example 31 (see the chemical structure) on page 73 of the specification. Claims 1-10, 12-60, 62-80, and 92 are pending.

Telephone Interview with Examiner Chu

Applicants' attorney gratefully thanks Examiner Chu for the courtesies shown during the telephone interviews on May 22nd and today. During the telephone interviews, the Examiner questioned whether the pending claims should be provisionally rejected under the judicially created doctrine of obviousness-type double patenting over U.S. Patent Application No. 10/532,273 ("the '273 Application"). The undersigned attorney pointed out that the presently claimed compounds of formula (1) include a substituted amino group at the R⁴ position (i.e., R⁴ is -NR⁵R⁶, with the proviso that R⁴ is not -NH₂). The compounds recited in claim 1 of the '273 Application can have a substituent R² at the same position as R⁴ in the presently claimed compounds. R² in the '273 Application can be, *inter alia*, amino (-NH₂). The claims of the '273 Application, however, do not recite that R² can be a <u>substituted</u> amino group. Based on this distinction, the Examiner agreed that a provisional double patenting rejection was not warranted.

The Examiner also pointed out that the Application Data Sheet submitted on April 9, 2004 does not provide the correct serial number for the parent PCT application (PCT Application No. PCT/IB2004/000355). The priority information for this application, however, is correctly provided in the first full paragraph on page 2 of the specification. Submitted herewith is a Supplemental Application Data Sheet with the correct serial number for the parent PCT application.

In view of the above amendments, the pending claims in this application are believed to be in condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue.

No fee is believed to be due with this submission. If, however, a fee is determined to be due, the Commissioner is authorized to charge it up to \$2,000.00 to our Deposit Account No. 04–0100.

Dated: May 25, 2006 Respectfully submitted,

By /Jay P. Lessler/
Jay P. Lessler
Registration No.: 41,151
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant